Virus Outbreak: Adimmune to begin vaccine trialsBy Kao Shih-ching / Staff reporterVaccine maker Adimmune Corp (國光生技) plans to conduct phase I clinical trials of its COVID-19 candidate vaccine next month to assess its safety, the firm said yesterday. The vaccine provider would cooperate with National Taiwan University Hospital (NTUH) for the trials, Pan said. Based on the results of phase I trials, we will select two dose levels that show the most promise to continue with phase II clinical trials,” Pan said. Adimmune, the nation’s largest flu vaccine provider, is a frontrunner in the local race to develop a COVID-19 vaccine, as it was the first to apply to the FDA to conduct human trials. Last week, Medigen Vaccine Biologics Corp (高端疫苗) applied to the FDA to run phase I human trials for its spike protein-based vaccine candidate, becoming second in the local race to produce a COVID-19 vaccine, company data showed.

Source: Taipei Times July 15, 2020 15:56 UTC